With 96 Percent Opt-In Rate, Actos Bladder Cancer Settlement Gets $2.37B Payment

(September 16, 2015, 10:44 AM EDT) -- DEERFIELD, Ill. — Takeda Pharmaceutical Co. Ltd. on Sept. 12 announced that more than 96 percent of eligible claimants have opted in to the $2.4 billion Actos bladder cancer settlement, triggering...
To view the full article, register now.